Frequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma

Frequent EGFR mutations in malignant pleural effusion of lung adenocarcinoma Shang-Gin Wu, Chien-Hung Gow, Chong-Jen Yu, Yih-Leong Chang, Chih-Hsin Yang, Ya-chieh Hsu, Jin-Yuan Shih*, Yung-Chie Lee, Pan-Chyr Yang 1 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 2 Division of Critical Care Medicine, Department of Emergency and Critical Care Medicine, Lotung Poh-Ai Hospital, Yi-Lan, Taiwan. 3 Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. 4 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 5 Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.

[1]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[2]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[3]  Young Tae Kim,et al.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Dieter Niederacher,et al.  Multistep carcinogenesis of breast cancer and tumour heterogeneity , 1997, Journal of Molecular Medicine.

[5]  S. Toyooka,et al.  The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  R. Light,et al.  Vascular endothelial growth factor in pleural fluid. , 1999, Chest.

[7]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[8]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[9]  J. Soh,et al.  Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer , 2006, International journal of cancer.

[10]  M. Raderer,et al.  Bevacizumab is active in malignant effusion. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Jin-Yuan Shih,et al.  EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. , 2005, The New England journal of medicine.

[12]  H. Sasaki,et al.  Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer , 2008, Journal of Cancer Research and Clinical Oncology.

[13]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[14]  M. Sonobe,et al.  Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma , 2005, British Journal of Cancer.

[15]  J. Soh,et al.  Impact of HER2 and EGFR gene status on gefitinib‐treated patients with nonsmall‐cell lung cancer , 2007, International journal of cancer.

[16]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[17]  H. Ho,et al.  Identification of differentially expressed proteins in human malignant pleural effusions , 2006, European Respiratory Journal.

[18]  K. Nishio,et al.  High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients , 2006, Cancer science.

[19]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Sasaki,et al.  A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. , 2006, Japanese journal of clinical oncology.

[21]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[22]  F. Emmrich,et al.  Vascular endothelial growth factor in pleural effusions of different origin , 2005, European Respiratory Journal.

[23]  J. Yokota,et al.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.

[24]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Thickett,et al.  Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions , 1999, Thorax.

[26]  F. Shepherd,et al.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Noguchi,et al.  Application of the p53 and K‐ras gene mutation patterns for cytologic diagnosis of recurrent lung carcinomas , 2000, Cancer.

[28]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[29]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[30]  Shih-Feng Tsai,et al.  High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.

[31]  J. Park,et al.  EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. , 2007, Cancer genetics and cytogenetics.

[32]  R. Light,et al.  Malignant pleural effusion: would the real cause please stand up? , 1997, The European respiratory journal.

[33]  K. Nishio,et al.  EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib , 2006, British Journal of Cancer.

[34]  T. Oyama,et al.  Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking , 2006, British Journal of Cancer.

[35]  Chan Zeng,et al.  Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels , 2006, Clinical Cancer Research.

[36]  K. Nackaerts,et al.  Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study , 2006, European Respiratory Journal.

[37]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[39]  Cheng-Ta Yang,et al.  Epidermal growth factor receptor mutations in cells from non-small cell lung cancer malignant pleural effusions. , 2006, Chang Gung medical journal.